Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies

NCT04681105 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04681105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04681105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
November 18, 2020
Completion date
August 5, 2025
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute leukemia, recurrent b acute lymphoblastic leukemia, recurrent blastic plasmacytoid dendritic cell neoplasm, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent hairy cell leukemia, recurrent hematologic malignancy, recurrent hodgkin lymphoma, recurrent t acute lymphoblastic leukemia, refractory acute leukemia, refractory b acute lymphoblastic leukemia, refractory blastic plasmacytoid dendritic cell neoplasm, refractory chronic myelogenous leukemia, bcr-abl1 positive, refractory hairy cell leukemia, refractory hematologic malignancy, refractory hodgkin lymphoma, refractory t acute lymphoblastic leukemia, systemic mastocytosis